Yi Ren1, Qi Yang1,2, Xisheng Weng1, Bin Feng3, Tim Luo4, Jin Lin1, Jin Jin1, Wenwei Qian1. 1. Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, 100730, China. 2. Department of Orthopedics, First Hospital of Harbin, Harbin, China. 3. Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, 100730, China. fengbin@pumch.cn. 4. Doctor of Medicine Program, University of Alberta, Edmonton, AB, Canada.
Abstract
BACKGROUND: Previous evidence suggested that perioperative anti-rheumatic therapy for patients receiving total knee arthroplasty (TKA) helped improve postoperative rehabilitation for rheumatoid arthritis (RA), yet long-term effects and outcomes of perioperative drug therapy in TKA presently remain unclear. This study investigated whether perioperative treatment with glucocorticoids (GC) and disease-modifying anti-rheumatic drugs (DMARDs) can improve clinical outcomes for patients with RA undergoing TKA. METHODS: Patients between January 2000 and December 2011 were allocated into three groups based on perioperative drug therapy: A, control group (no GC or DMARDs), B, DMARD group (DMARDs given without GC), and C, co-therapy group (DMARDs plus GC). The patients were followed up for average 11.4 years. Baseline characteristics, pre- and post-operative Hospital for Special Surgery score (HSS), laboratory parameters, and complications were recorded by follow-up. RESULTS: Fifty-six RA patients undergoing 91 TKAs were included in this study. Patients who received perioperative GC with DMARDs (group C) achieved larger/increased range of motion (ROM) (C:122.17 vs A:108.31 vs B:108.07, p = 0.001, partial eta squared (η2 p) = 0.18) at 1 year, better HSS score (C, 83.01 vs A, 79.23 vs B, 77.35, p = 0.049, η2 p = 0.067), pain relief (C, 1.09 vs A, 1.17 vs B, 1.75, p = 0.02, η2 p = 0.094), and ROM (C, 130.81 vs A, 112.82 vs B, 113.58, p = 0.001, η2 p = 0.142) at latest follow-up comparing with the other treatment groups. No differences were noted in laboratory tests, blood loss, volume of transfusion, or complications among groups. CONCLUSIONS: Compared with the other perioperative anti-rheumatic treatments, the combination of GC and DMARDs results in improved HSS score, better function, larger range of motion, and reduced postoperative pain for TKA patients with RA in the long term. Further investigation is warranted to look for a better understanding of more specific medication effects and strike a good balance between the benefits and complications for long-term pharmacotherapy.
BACKGROUND: Previous evidence suggested that perioperative anti-rheumatic therapy for patients receiving total knee arthroplasty (TKA) helped improve postoperative rehabilitation for rheumatoid arthritis (RA), yet long-term effects and outcomes of perioperative drug therapy in TKA presently remain unclear. This study investigated whether perioperative treatment with glucocorticoids (GC) and disease-modifying anti-rheumatic drugs (DMARDs) can improve clinical outcomes for patients with RA undergoing TKA. METHODS:Patients between January 2000 and December 2011 were allocated into three groups based on perioperative drug therapy: A, control group (no GC or DMARDs), B, DMARD group (DMARDs given without GC), and C, co-therapy group (DMARDs plus GC). The patients were followed up for average 11.4 years. Baseline characteristics, pre- and post-operative Hospital for Special Surgery score (HSS), laboratory parameters, and complications were recorded by follow-up. RESULTS: Fifty-six RApatients undergoing 91 TKAs were included in this study. Patients who received perioperative GC with DMARDs (group C) achieved larger/increased range of motion (ROM) (C:122.17 vs A:108.31 vs B:108.07, p = 0.001, partial eta squared (η2 p) = 0.18) at 1 year, better HSS score (C, 83.01 vs A, 79.23 vs B, 77.35, p = 0.049, η2 p = 0.067), pain relief (C, 1.09 vs A, 1.17 vs B, 1.75, p = 0.02, η2 p = 0.094), and ROM (C, 130.81 vs A, 112.82 vs B, 113.58, p = 0.001, η2 p = 0.142) at latest follow-up comparing with the other treatment groups. No differences were noted in laboratory tests, blood loss, volume of transfusion, or complications among groups. CONCLUSIONS: Compared with the other perioperative anti-rheumatic treatments, the combination of GC and DMARDs results in improved HSS score, better function, larger range of motion, and reduced postoperative pain for TKA patients with RA in the long term. Further investigation is warranted to look for a better understanding of more specific medication effects and strike a good balance between the benefits and complications for long-term pharmacotherapy.
Authors: Zachary J LoVerde; Lisa A Mandl; Beverly K Johnson; Mark P Figgie; Friedrich Boettner; Yuo-Yu Lee; Susan M Goodman Journal: J Rheumatol Date: 2015-05-01 Impact factor: 4.666
Authors: Cindy Strehl; Marlies C van der Goes; Johannes W J Bijlsma; Johannes W G Jacobs; Frank Buttgereit Journal: Expert Opin Investig Drugs Date: 2017-01-03 Impact factor: 6.206
Authors: Inmaculada del Rincón; Daniel F Battafarano; Jose F Restrepo; John M Erikson; Agustín Escalante Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: M C van der Goes; J N Hoes; M J Cramer; M J van der Veen; J H van der Werf; J W J Bijlsma; J W G Jacobs Journal: Clin Exp Rheumatol Date: 2014-01-24 Impact factor: 4.473
Authors: Samuel J W White; William A Ranson; Brian Cho; Zoe B Cheung; Ivan Ye; Oscar Carrillo; Jun S Kim; Samuel K Cho Journal: Spine Deform Date: 2019-09
Authors: Seung Ah Lee; Seung-Baik Kang; Chong Bum Chang; Moon Jong Chang; Young Jun Kim; Min Kyu Song; Jin Hwa Jeong Journal: PLoS One Date: 2018-10-11 Impact factor: 3.240